Australia Health

Therapeutic wound care company AVITA Medical (ASX:AVH) reported record second-quarter net revenue of US$21.7 million.

ResMed (ASX:RMD) reported a 9% increase in fourth-quarter revenue to reach US$1.5 billion.

Wellnex Life (ASX:WNX) agreed to sell its Pain Away business for up to $21.3 million in cash.

Osteopore (ASX:OSX) has secured a three-year distribution deal with Al-Umnia Medical across five Middle Eastern nations.

ReNerve (ASX:RNV) has received marketing approval in the Philippines for its NervAlign nerve cuff device.

Clarity Pharmaceuticals (ASX:CU6) reported two new complete responses in its SECuRE prostate cancer trial.

Memphasys (ASX:MEM) executed an exclusive $350,000 commercialisation agreement with TK Biotech in Poland.

Neuren Pharmaceuticals (ASX:NEU) reported second-quarter DAYBUE net sales of US$125 million through partner Acadia Pharmaceuticals (NASDAQ:ACAD).

Biotechnology firm AdAlta (ASX:1AD) reported that a trial patient achieved two years of recurrence-free cancer survival.

Amplia Therapeutics (ASX:ATX) partnered with Eli Lilly & Company (NYSE:LLY) for a Phase 1b/2b trial starting in late 2026.

Neurotech International (ASX:NTI) has secured binding commitments to raise $4.5 million to advance its Phase 3 paediatric autism clinical trial.

Entropy Neurodynamics (ASX:ENP) has secured ethics approval for a Phase 1b/2a clinical trial evaluating drug TRP-8803 in 72 patients.